Drug intelligence / Profile preview

ondansetron hydrochloride + sumatriptan

Development stage
Approved
Lead developer
Puretek
Modality
Small Molecules
Administration
Oral
01

Overview

**Ondansetron hydrochloride + sumatriptan** is an oral fixed-combination product or kit pairing the antiemetic **ondansetron**, a selective serotonin 5-HT3 receptor antagonist, with **sumatriptan**, a serotonin 5-HT1B/5-HT1D receptor agonist used for acute migraine treatment. The combination appears intended to address both migraine pain and associated nausea/vomiting in patients with migraine. Publicly identifiable evidence supports the existence of an unapproved U.S. product labeled **Sumansetron**, packaged by PureTek, but the available DailyMed record is internally inconsistent and primarily reproduces ondansetron labeling text rather than a clear, fully characterized combination-drug label; accordingly, this asset should be treated as a real but poorly documented combination product rather than a well-established approved branded medicine.

Brand names
Sumansetron
Other names
ondansetron hydrochloride + sumatriptansumatriptan succinate + ondansetron
02

Targets

HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on ondansetron hydrochloride + sumatriptan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ondansetron hydrochloride + sumatriptan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call